. 2022 May 13;9:913678. doi: 10.3389/fsurg.2022.913678

Table 3.

Associations between overall survival, disease-free survival and clinical variables.

	Overall Survival % [CI_95%]		p-value^a
	36 months	60 months	p-value^a
Metastasis
Unilateral	64.8 [51.1–82.2]	43.1 [29.2–63.6]	0.0022
Bilateral	49.6 [35.1–70.1]	22.2 [11.4–43.7]
Number of pulmonary metastases
One	61.9 [48.8–78.6]	48.7 [35.4–67.1]	0.0009
More than one	50.6 [35.1–73.1]	–
Postmetastasectomy CEA^b
Normal	72.4 [59.2–88.6]	49.3 [34.6–70.5]	0.0009
Abnormal	38.4 [24.2–60.9]	17.5 [7.89–38.7]
Extrapulmonary metastasis
Liver	41.8 [23.8–73.3]	5.96 [0.89–39.8]	0.0170
Other	59.8 [42.6–84.1]	44.4 [28.0–71.9]
None	64.9 [50.1–84.1]	44.9 [28.7–68.6]
Disease free interval
≤12 months	38.8 [21.0–71.9]	–	<0.01
>12 months	62.9 [51.2–77.3]	41.4 [29.6–57.9]
	Disease Free Survival % [CI_95%]		p-value^a
	36 months	60 months	p-value^a
Metastasis
Unilateral	41.1 [27.5–61.7]	34.7 [21.9–55.0]	0.0026
Bilateral	18.5 [8.80–38.9]	13.8 [5.45–35.3]
Number of pulmonary metastases
One	58.0 [40.3–83.3]	47.4 [30.0–74.9]	0.0027
More than one	16.2 [8.15–32.4]	13.5 [6.23–29.5]
Stage
I,II and III	39.0 [27.4–55.6]	27.5 [16.6–45.6]	0.0048
IV^c	5.91 [0.89–39.3]	–

^{^a}

Log-Rank test.

^{^b}

CEA: carcinoembryonic antigen.

^{^c}

Stage IV at diagnosis.